Therapeutic effect of a TM4SF5-specific monoclonal antibody against colon cancer in a mouse model

Young-Eun Kim1,*, Sanghoon Kwon2,*, Guang Wu2,*, Dongbum Kim2, Byoung Kwon Park3, Jeong-A Park1, Kyung-Chan Choi4, Doo-Sik Kim5, Hyung-Joo Kwon2,3 and Younghee Lee1

1 Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Chungbuk, Republic of Korea
2 Center for Medical Science Research, College of Medicine, Hallym University, Gangwon-do, Republic of Korea
3 Department of Microbiology, College of Medicine, Hallym University, Gangwon-do, Republic of Korea
4 Department of Pathology, College of Medicine, Hallym University, Gangwon-do, Republic of Korea
5 Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea

* These authors contributed equally to this work

Correspondence to: Kwon HJ, email: hjookwon@hallym.ac.kr
Younghee Lee, email: yhl4177@cbnu.ac.kr

Keywords: TM4SF5, monoclonal antibody, colon cancer, therapeutics, animal model

ABSTRACT

Transmembrane 4 superfamily member 5 protein (TM4SF5) is presumed to serve as a molecular target to prevent or treat hepatocellular carcinoma (HCC) and colon cancer in a mouse model. Previously, we reported the efficacy of anti-cancer peptide vaccine targeting TM4SF5. In addition, we reported an anti-proliferative effect of anti-TM4SF5 monoclonal antibody in HCC. Here, we investigated expression of TM4SF5 in 45 primary colon cancer tissues. Almost all of the colon cancer tissues expressed TM4SF5 based on immunohistochemistry using anti-TM4SF5 monoclonal antibody. The treatment of human colon cancer cells with anti-TM4SF5 antibody reduced growth of TM4SF5 expressing cells and enhanced expression of E-cadherin and β-catenin. Using mouse colon cancer models, we then evaluated the in vivo anti-cancer effect of anti-TM4SF5 antibody. Injection of the antibody significantly reduced growth of tumors priorly established by subcutaneous injection of human colon cancer cells HT-29 in a xenograft setting. We obtained similar results with mouse colon cancer cell line CT-26 in an allograft setting. Therefore, we suggest that the TM4SF5-specific monoclonal antibody has a therapeutic effect against colon cancer.

INTRODUCTION

Colon cancer is one of the most common cancers in the world. It has high mortality, about 30% ~ 40% in the United States and Europe, and is more common in developed countries than in undeveloped countries [1]. As the number of deaths from colon cancer is increasing worldwide, prevention, early diagnosis, and efficacious therapy are critically important [2]. Surgery, chemotherapy, and radiotherapy are generally performed, alone or in combination, to treat patients with colon cancer [3-5]. Immunotherapeutic approaches using peptide vaccines, dendritic cell-based cancer vaccines, whole tumor cell vaccines, viral vector-based cancer vaccines, adoptive cell transfer therapy, antibody-based cancer immunotherapy, and cytokine therapy are another treatment option [6]. Immunotherapy has gained attention as the therapeutics has narrow specificity and therefore may have fewer side effects [7-10].

Understanding the receptor-mediated signaling pathways involved in cancer development is important for designing cancer-specific therapeutics targeting extracellular molecules. Several well-known oncogenic pathways have been implicated in the pathogenesis of cancers, including the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (HGF/c-Met),...
and vascular endothelial growth factor (VEGF) pathways [11-15]. Mutations in oncogenes and tumor suppressor genes involved in these receptor signaling pathways are commonly observed in several cancers including colon cancer [15,16].

In the past decade, small molecule inhibitors and antibodies targeting these receptors have been widely investigated in both preclinical and clinical applications to block the pathogenesis of cancers [17-21]. Bevacizumab (Avastin) is a recombinant humanized monoclonal antibody against VEGF that has proven to be effective for the treatment of colon cancer, renal cancer, ovarian cancer, etc. [19-21]. Other neutralizing monoclonal antibodies against EGFR (cetuximab and panitumumab) have been approved as therapeutics for colon cancer [22,23].

Tetraspanins, also known as transmembrane 4 superfamily (TM4SF) members, can associate with various molecules such as integrins, membrane receptors, immunoglobulin superfamily proteins, and other tetraspanins to form a multimolecular tetraspanin web [24,25]. Because of the great heterogeneity in the composition of the web, tetraspanins are widely involved in regulation of cell differentiation, activation, growth, and migration [26-30]. Recent reports revealed that tetraspanins function as both suppressors and promoters of metastasis depending on the particular tetraspanins [31]. Tetraspanins have thus gained attention as diagnostic and prognostic markers, as well as therapeutic targets for preventing tumor progression [31,32].

TM4SF5, one of the tetraspanins, was previously implicated in hepatocellular carcinoma (HCC) [33,34]. TM4SF5 is involved in epithelial-mesenchymal transition, loss of contact inhibition, and regulation of VEGF-mediated angiogenesis through cooperation with integrins [34,35]. TM4SF5 expression enhanced migration and invasion, which may contribute to effective metastasis [36]. Previously, we established a method to induce production of antibodies using peptide epitopes in combination with CpG-DNA-liposome complex without carriers [37]. Using this technology, we showed that TM4SF5 can serve as a molecular target for HCC and colon cancer: a peptide vaccine targeting TM4SF5 had preventive or therapeutic effects against HCC and colon cancer in mouse models [38-41]. Therefore, we postulated that TM4SF5-specific monoclonal antibody can serve as a therapeutic antibody to treat these cancers and we recently proved that injection of anti-TM4SF5 antibody can suppress the growth of HCC tumor in a mouse model [42].

In this study, we investigated expression of TM4SF5 in colon cancer tissues and the therapeutic effect of the TM4SF5-specific monoclonal antibody against colon cancer in a mouse model. We confirmed that injection of anti-TM4SF5 antibody reduced the growth of tumors derived from pre-implanted colon cancer cells in mice.

RESULTS

Expression of the TM4SF5 protein in human colon cancer tissues

In order to investigate expression of the TM4SF5 protein in colon cancer tissues, we performed immunohistochemical staining with the anti-TM4SF5 monoclonal antibody. We analyzed 45 samples of primary colon cancer tissues along with normal colon tissue samples as a control (tissue microarray A203VII). As shown in Figure 1A, there was no expression of TM4SF5 in normal colon tissues. However, almost all of the colon cancer tissues (44 among 45 samples) expressed TM4SF5 (97.8%, staining in >11% of tumor cells) (Figure 1B, Table 1). Approximately 35.6% of colon cancer tissue samples expressed TM4SF5 in ≥75% of tumor cells and ~40% of colon cancer tissues were positive for TM4SF5 expression in 74-50% of tumor cells. It is thus concluded that expression of TM4SF5 can serve as a marker of colon cancer. However, the levels of TM4SF5 expression did not correlate with colon tumor grade or stage (Table 2).

Expression of TM4SF5 in human colon cancer cell lines and the effect of anti-TM4SF5 antibody on the growth of TM4SF5 expressing cells

To validate TM4SF5 as an efficacious target for anti-colon cancer therapy, we first examined the expression of TM4SF5 mRNA in human colon cancer cell lines. As shown in Figure 2A, HT-29 and LoVo cells

| Colon tissue sections (AccuMax Array) | n | TM4SF5 positive (%) | Number (%) of cases expressing TM4SF5 |
|--------------------------------------|---|---------------------|---------------------------------------|
| A203VII                              | 45| 97.8                | ≥75% 16 (35.6) 74-50% 18 (40.0) 49-11% 10 (22.2) ≤10% 1 (2.2) |

Percentages in parentheses were calculated as the number of TM4SF5-positive samples for each quartile, divided by the total number of samples in each tumor type.
Table 2: Expression of TM4SF5 in colon cancer tissues.

A203 (VII) Colon cancer tissues

| No. | Sex | Age | TNM stage | Grade | Ab staining |
|-----|-----|-----|-----------|-------|-------------|
| 1   | M   | 63  | T3N0M0    | G2    | +++         |
| 2   | M   | 33  | T3N0M0    | G2    | ++++        |
| 3   | F   | 72  | T3N0M0    | G2    | +++         |
| 4   | M   | 72  | T3N0M0    | G2    | ++++        |
| 5   | M   | 72  | T3N1M0    | G2    | ++          |
| 6   | F   | 49  | T3N0M0    | G2    | +++         |
| 7   | F   | 67  | T4N0M0    | G2    | +           |
| 8   | M   | 51  | T3N1M0    | G2    | +++         |
| 9   | M   | 63  | T2N0M0    | G2    | ++          |
| 10  | M   | 57  | T3N0M0    | G2    | +++         |
| 11  | M   | 65  | T3N0M0    | G2    | ++          |
| 12  | F   | 48  | T4N1M0    | G2    | ++++        |
| 13  | F   | 50  | T3N2M0    | G2    | +++         |
| 14  | M   | 27  | T3N0M0    | G2    | ++          |
| 15  | F   | 39  | T3N0M0    | G2    | ++          |
| 16  | F   | 69  | T3N1M1    | G2    | ++          |
| 17  | F   | 51  | T4N0M1    |       | +++         |
| 18  | M   | 50  | T3N0M     | G2    | +++         |
| 19  | F   | 77  | T4N1M0    | G2    | ++          |
| 20  | F   | 77  | T3N0M0    | G2    | +++         |
| 21  | F   | 45  | T3N2M0    | G2    | +++         |
| 22  | M   | 58  | T3N0M0    | G2    | +++         |
| 23  | F   | 39  | T3N0M0    | G2    | +++         |
| 24  | F   | 47  | T4N0M0    | G2    | +++         |
| 25  | F   | 75  | T3N0M0    | G2    | +++         |
| 26  | F   | 71  | T3N1M0    | G2    | +++         |
| 27  | F   | 40  | T4N2M1    | G2    | ++          |
| 28  | M   | 70  | T4N1M1    | G2    | ++++++++++  |
| 29  | M   | 67  | T3N0M0    | G2    | +++         |
| 30  | M   | 43  | T3N1M0    | G2    | +++         |
| 31  | F   | 63  | T4N0M0    | mucinous | +++         |
| 32  | F   | 53  | T3N0M0    | G1    | +++         |
| 33  | M   | 52  | T3N1M0    | G1    | +++         |
| 34  | M   | 59  | T3N0M0    | G2    | +++         |
| 35  | M   | 41  | T4N2M0    | G2    | +++         |
| 36  | M   | 56  | T3N1M0    | G1    | ++          |
| 37  | M   | 64  | T3N2M0    | G1    | +++         |
| 38  | F   | 65  | T1N0M0    | G1    | +++         |
| 39  | M   | 69  | T4N1M0    | G2    | +++         |
| 40  | F   | 58  | T3N1M0    | G2    | +++         |
| 41  | M   | 57  | T3N0M0    | G3    | ++          |
| 42  | M   | 56  | T3N1M0    | G3    | ++          |
| 43  | F   | 52  | T3N2M0    | G3    | +++         |
| 44  | F   | 53  | T3N2M0    | G2    | +++         |
| 45  | M   | 68  | T3N0M0    | G2    | +++         |

≥75% (4, ++++), 50-74% (3, +++), 11-49% (2, ++), ≤10% (1, +)
expressed human TM4SF5 mRNA, but HCT116 did not express TM4SF5. Therefore, these cell lines can be used as a model. Expression of TM4SF5 was also detected in a mouse colon cancer cell line CT-26, as previously reported [40], and therefore CT-26 cells were used for a mouse allograft model.

We then investigated the effect of the anti-TM4SF5 monoclonal antibody on colon cancer cell growth. The growth of HT-29 cells and LoVo cells expressing TM4SF5 was delayed by the antibody treatment. However, there was no change with control IgG treatment. In contrast, anti-TM4SF5 antibody did not induce a significant change in the growth of HCT116 cells, which did not express TM4SF5 (Figure 2B). Therefore, we conclude that the anti-TM4SF5 antibody has an anti-proliferative effect on human colon cancer cells expressing TM4SF5 in vitro.

Figure 1: Expression of TM4SF5 in colon cancer tissues. An immunohistochemical analysis of colon cancer tissues was performed with anti-TM4SF5 monoclonal antibody and colon cancer tissue arrays. A. Normal colon tissue. B. Examples of colon cancer tissues with ≥75%, 74-50%, 49-11%, and ≤10% of tumor cells expressing TM4SF5. Scale bars; left panel, 200 µm. right panel, 50 µm.

Figure 2: Expression of TM4SF5 in colon cancer cells and the effect of anti-TM4SF5 antibody on the growth of colon cancer cells. A. The expression levels of TM4SF5 mRNA in the indicated human (left) and mouse (right) colon cancer cell lines were analyzed by RT-PCR. B. Effect of anti-TM4SF5 antibody on the growth of human colon cancer cells. Cell growth was measured by an MTT assay. Each bar is expressed as the mean ± standard deviation of three experiments. **P< 0.01. (vs normal IgG control).
Effect of the anti-hTM4SF5 monoclonal antibody on the expression of E-cadherin and β-catenin in human colon cancer cells

E-cadherin is a major protein involved in cell-cell interaction. Previously, we found that treatment of HCC cells expressing TM4SF5 with anti-TM4SF5 antibody enhances expression of E-cadherin [42]. We therefore checked expression of E-cadherin using confocal microscopy and Western blotting analysis. As shown in Figures 3A and 3B, treatment of HT-29 cells with the anti-TM4SF5 antibody enhanced expression of E-cadherin compared to the untreated control or IgG-treated control. In contrast, there was no prominent difference in HCT116 cells.

In addition to E-cadherin, β-catenin is an essential component of the cell adhesion complex [43]. We therefore also investigated expression of β-catenin (Figure 4). Treatment of HT-29 cells with anti-TM4SF5 antibody clearly enhanced expression of β-catenin. However, there was no difference in the untreated control or IgG-treated

Figure 3: Enhanced expression of E-cadherin in TM4SF5 expressing cells after treatment with anti-TM4SF5 antibody.
A. The expression levels of E-cadherin in the colon cancer cells, HT-29 and HCT116 cells, were analyzed by confocal microscopy after treatment with PBS, normal IgG, or the anti-TM4SF5 monoclonal antibody for 3 days. The secondary antibody control without the anti-E-cadherin antibody staining is shown as (-) E-cadherin. B. (Top) The expression levels of E-cadherin in the colon cancer cells were analyzed by Western blotting. The expression levels of GAPDH are shown as a loading control. These are representative of at least three independent experiments. (Bottom) The expression levels of E-cadherin are shown taking the value of the PBS control group after treatment for 1 day as 1.0. *p<0.05, mean ± SD.
control. Treatment of HCT116 cells with anti-TM4SF5 antibody induced no change. These results suggest that enhanced cell-cell interaction induced by treatment with TM4SF5 antibody contributes to contact inhibition in TM4SF5 expressing cells.

We previously showed that the anti-TM4SF5 antibody induced changes in actin polymerization and formation of focal adhesion sites in HCC cells based on phalloidin and paxillin staining [42]. However, we found that there was no change in colon cancer cells (data not shown). Other changes observed in TM4SF5 expressing HCC cells treated with anti-TM4SF5 antibody were nuclear translocation of the CDK inhibitor p27kip1 and increased activity of a small GTP protein RhoA [42]. Therefore, we checked these aspects and found that anti-TM4SF5 did not induce a prominent change in colon cancer cells (data not shown). Therefore, it is likely that the specific action mechanism of anti-TM4SF5 differs depending on the specific types of tissue expressing TM4SF5.

Localization of the injected anti-TM4SF5 monoclonal antibody on colon tumors in vivo

As the anti-TM4SF5 monoclonal antibody can inhibit the growth of colon cancer cell lines in vitro, we next investigated the in vivo effect of the antibody on tumors. First, we determined the distribution of the anti-TM4SF5 antibody after injection into mice. The anti-TM4SF5 antibody and mouse IgG2a control were conjugated with DyLight 755 (a fluorescent dye) and

Figure 4: Enhanced expression of β-catenin in TM4SF5 expressing cells after treatment with anti-TM4SF5 antibody. A. The expression levels of β-catenin in the colon cancer cells, HT-29 and HCT116 cells, were analyzed by confocal microscopy after treatment with PBS, normal IgG, or the anti-TM4SF5 monoclonal antibody for 5 days. B. (Top) The expression levels of β-catenin in the colon cancer cells were analyzed by Western blotting. The expression levels of GAPDH are shown as a loading control. These are representative of at least three experiments. (Bottom) The band intensity was measured and normalized with the amount of GAPDH. Relative expression levels of β-catenin are shown taking the value of the PBS control group after treatment for 2 days as 1.0. *p<0.05, mean ± SD.
Figure 5: Biodistribution of the anti-TM4SF5 monoclonal antibody in colon tumor tissue. BALB/c mice were injected with PBS as a control or CT-26 cells to generate tumor-bearing mice. A. DyLight 755-labeled IgG2a isotype control or the anti-TM4SF5 monoclonal antibody was injected into the intraperitoneal cavity of the mice, and the whole body fluorescence was examined using a real-time IVIS Imaging System 200 Series at the starting time point and after 72 h. B. The mice were dissected and the localization of the antibody was examined using the IVIS imaging system (upper panel). Tumor tissues were taken out and placed to the left of the mice (lower panel). C. The harvested tumor tissue was frozen, and the microsection samples were stained with SYTOX Green dye for nuclei staining and analyzed by confocal microscopy. Scale bars, 20 µm. These are representative of two independent experiments with four mice per each treatment.
the DyLight-labeled antibodies were injected into the intraperitoneal cavity of control mice or mice harboring CT-26 cell derived tumors. After 72 h, the distribution of the labeled antibody was quantified by measuring the total photon flux (photons/sec) of the fluorescence. As shown in Figures 5A and 5B, the DyLight 755-labeled anti-TM4SF5 monoclonal antibody was localized in the tumors, whereas the DyLight 755-labeled IgG2a control was not detected in the mice. When we cut out the tumor mass and analyzed microsections of the frozen tissue, we found that many of the tumor cells were stained with the DyLight 755-labeled anti-TM4SF5 antibody (Figure 5C). In contrast, we could not detect any labeling in the control sections obtained from mice injected with DyLight 755-labeled

**Figure 6: Therapeutic efficacy of the anti-TM4SF5 monoclonal antibody against colon tumor growth in a xenograft mouse model.** A mouse xenograft model was established by the implantation of HT-29 cells in BALB/cAnCg-nu/nu mice. When the tumors reached 5 mm in diameter, PBS, normal IgG or the anti-TM4SF5 monoclonal antibody was injected into the mice and tumor growth was monitored for 30 days (n=8 each). Control mice injected with PBS are shown as a control (n=6). A. Macroscopic appearance of tumor bearing mice and dissected tumor tissues. B. Tumor volume (width x length/2). Data are represented as mean ± standard deviation. C. Individual tumor weights for each treatment group. Mean values are indicated as a horizontal bar. D. Individual body weights for each treatment group. Data are represented as mean ± standard deviation. E. Expression of TM4SF5 in the tumor tissues. TM4SF5 expression was confirmed by an immunohistochemical analysis using the anti-TM4SF5 monoclonal antibody. This image is representative of colon tumor tissues. The TM4SF5 positive area is expressed as a brown color. H&E and IHC represent hematoxylin and eosin staining and immunohistochemistry, respectively. Scale bars, 20 μm. **p<0.01, mean ± SD.
IgG2a control. Therefore, the anti-hTM4SF5 monoclonal antibody can target colon tumor cells expressing TM4SF5 in vivo.

**Anti-TM4SF5 monoclonal antibody inhibits growth of colon tumors in a xenograft mouse model**

To evaluate the efficacy of the anti-TM4SF5 antibody against colon cancer in mice, we determined the effect of the anti-hTM4SF5 antibody on the growth of colon cancer cells in vivo using human cell line HT-29 and a xenograft mouse model. We injected nude mice subcutaneously in the dorsal right flank with HT-29 cells and allowed the tumors to grow. When the tumor size reached 5 mm in diameter, we injected the animals twice a week in the intraperitoneal cavity with PBS, normal mouse IgG, or anti-TM4SF5 monoclonal antibody. Based on the tumor volume and weight, anti-TM4SF5 monoclonal antibody attenuated the progression of tumor growth.

**Figure 7: Therapeutic efficacy of the anti-TM4SF5 monoclonal antibody against colon tumor growth in an allograft mouse model.** A mouse allograft model was established by implantation of CT-26 cells in BALB/c mice. PBS, normal IgG or the anti-TM4SF5 monoclonal antibody was injected intraperitoneally into the tumor bearing mice when the tumors reached 5 mm in diameter, and tumor growth was monitored for 18 days (n=8 each). Control mice injected with PBS are shown as a control (n=8). A. Macroscopic appearance of tumor bearing mice and dissected tumor tissues. B. Tumor volume (width^2 x length/2). Data are represented as mean ± standard deviation. C. Individual tumor weights. Mean values are indicated as a horizontal bar. D. Individual body weights for each treatment group. Data are represented as mean ± standard deviation. **p<0.01, mean ± SD.
of colon tumors compared with PBS or normal mouse IgG (Figures 6A-C). The antibody treatment did not affect the body weight during the experiment (Figure 6D). The expression of TM4SF5 in colon tumor tissue was confirmed by immunostaining with the anti-TM4SF5 antibody (Figure 6E). Analysis of the results of xenograft experiments revealed that the anti-TM4SF5 monoclonal antibody targeting colon tumor cells can decrease tumor growth in vivo.

**Anti-TM4SF5 monoclonal antibody inhibits colon cancer growth in an allograft mouse model**

To investigate the effect of anti-TM4SF5 antibody on colon tumors, we used mouse CT-26 cells and a mouse tumor allograft model. As shown in Figures 7A-C, treatment with the anti-TM4SF5 antibody significantly suppressed the progression of colon tumors derived from CT-26 cells. The antibody treatment did not affect the body weight during the experiment (Figure 7D). Together these experiments suggest that the anti-TM4SF5 monoclonal antibody can inhibit growth of colon tumors in an allograft mouse model.

**DISCUSSION**

It has been reported that TM4SF5 mRNA is expressed in colon carcinoma, pancreatic tumors, and HCC [33]. We recently investigated the expression of the TM4SF5 protein in human HCC specimens using the anti-TM4SF5 monoclonal antibody and found that TM4SF5 protein was expressed in all of the 105 HCC tissues examined [42]. In addition to HCC, TM4SF5 expression was also detected in colon cancer and pancreatic cancer tissues [42]. Here, we investigated expression of the TM4SF5 protein in colon cancer tissues in detail and confirmed that the TM4SF5 protein is overexpressed in human colon cancer tissues. In addition, we investigated *in vitro* and *in vivo* effects of anti-TM4SF5 antibody using colon cancer cell lines and mouse models.

This is the first report directly showing expression of TM4SF5 protein in a large number of colon cancer tissues. Based on the immunohistochemistry data of colon cancer tissue microarrays, TM4SF5 expression was detected in almost all of the colon cancer tissue samples we examined, at various expression levels (Table 1). The expression of TM4SF5 in some colon cancer cell lines was also examined. Expression of TM4SF5 is thus likely to be associated with onset or progression of colon cancer cells and TM4SF5 can be a target to treat colon cancer.

We also confirmed that the anti-TM4SF5 antibody inhibited growth of human colon cancer cell lines expressing TM4SF5. Furthermore, we found that the expression of E-cadherin and β-catenin was enhanced by anti-TM4SF5 antibody. These results suggest that treatment with anti-TM4SF5 antibody restores contact inhibition, resulting in reduced cell growth. However, some mechanisms of action induced by anti-TM4SF5 antibody in colon cancer appear to be different from HCC. For example, nuclear localization of p27kip1 was detected in HCC cells treated with the anti-TM4SF5 antibody; however a prominent difference after treatment of colon cancer cells with anti-TM4SF5 antibody was not observed. Considering a previous report that p27kip1 alterations such as cytoplasmic p27kip1 localization or p27kip1 loss are associated with superior prognosis of colon cancer patients [44], functional recovery of p27kip1 in the nucleus may not be a viable target of anti-tumor activities in colon cancer. Nonetheless, we can conclude that the anti-TM4SF5 antibody may have therapeutic effects on colon cancer.

We therefore validated anti-TM4SF5 monoclonal antibody as an efficacious therapeutic against colon cancer *in vivo* using mouse xenograft and allograft models. To confirm the anti-tumor activity of the anti-TM4SF5 monoclonal antibody against colon cancer *in vivo*, we administered the anti-TM4SF5 antibody into mice bearing tumors pre-established by injection with human or mouse colon cancer cells. The anti-TM4SF5 monoclonal antibody was specifically localized in the tumor tissues (Figure 5) and significantly suppressed tumor growth without prominent side effects (Figures 6 and 7). The obtained results demonstrate that this anti-TM4SF5 monoclonal antibody has therapeutic effects in mouse models of colon cancer, and suggest that injection with anti-TM4SF5 antibody can be an efficacious therapies to treat colon cancer in humans.

Considering that TM4SF5 expression was detected also in pancreatic cancer tissues [33,42], we can extend the present research to investigate the expression of TM4SF5 protein in a number of pancreatic cancer tissues and evaluate the efficacy of the anti-TM4SF5 antibody as a therapeutic in a mouse model. Through such research, we can validate the strategy described here to treat pancreatic cancer in the future. As pancreatic cancer is notoriously difficult to treat, the outcome of such research would provide valuable information. Recently, high expression of TM4SF5 in esophageal cancer tissues was reported: a high level of TM4SF5 expression was detected in about 45% of evaluated cases and high TM4SF5 expression was associated with cancer progression and poor patient survival [45]. It is thus possible that anti-TM4SF5 antibody also has anti-cancer effects on esophageal cancer.

To strengthen the anti-cancer effects of the targeted therapy using the anti-TM4SF5 antibody, development of an antibody-drug conjugate may be a better choice, as previously reported [46,47]. For rational and safer antibody therapeutics, tremendous efforts to understand the action mechanism, produce humanized antibodies, and validate *in vivo* effects of the antibodies in detail are warranted.
MATERIALS AND METHODS

Production of the mouse anti-human TM4SF5 monoclonal antibody

As described previously [37], we obtained hybridoma cells producing the anti-hTM4SF5 peptide-specific monoclonal antibody after immunization of BALB/c mice with the hTM4SF5R2-3 peptide derived from human TM4SF5 (138NRTLWDRCEAPPRV151) and CpG-DNA coencapsulated in a DOPE:CHEMS complex. The anti-TM4SF5 monoclonal antibody was purified from the ascitic fluid by protein A column chromatography. As the isotype of anti-TM4SF5 monoclonal antibody is IgG2a, the real control is normal IgG2a. However, we previously confirmed that normal IgG can be used as a control instead of IgG2a [42]. Therefore, we used normal IgG or IgG2a as an antibody control for in vitro and in vivo experiments.

Tissue microarrays and immunohistochemistry

For the colon cancer tissue analysis, formalin-fixed, paraffin-embedded AccuMax tissue arrays were purchased from ISUABXIS with the approval of the Institutional Review Board in Hallym University. The colon cancer tissue array (A203VII) is composed of 45 cases of colon cancer tissues in duplicate and 8 normal colon tissues. The slides were deparaffinized with xylene and rehydrated in ethanol, and endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 15 min. For antigen retrieval, all sections were boiled in a citrate buffer (pH 6.0) (ScyTek Laboratories) for 15 min. The slides were incubated overnight in PBST (PBS, Tween 0.2%) containing the anti-TM4SF5 monoclonal antibody (10 µg/ml) at 4°C, followed by incubation with biotinylated anti-mouse IgG antibody (Histostain Plus kit, Invitrogen). They were sequentially reacted with streptavidin-conjugated peroxidase, 3',3'-diaminobenzidin (0.5 mg/ml) and hydrogen peroxide and then counterstained with hematoxylin. After rinsing, the sections were mounted, dehydrated, and covered with cover slips. All images were examined using a Nikon Eclipse E-200 microscope. The percentages of cells expressing TM4SF5 were calculated as the number of TM4SF5-positive cells divided by the total number of cells in each tumor type.

Cell culture

The human colon cancer cell lines HT-29, LoVo, and HCT116, and the mouse colon cancer cell line CT-26 were obtained from the Korean Cell Line Bank. CT-26 cells were maintained in a DMEM medium containing 10% fetal bovine serum (FBS; HyClone), 2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. The other cell lines were maintained in an RPMI 1640 medium with 10% FBS, 25 mM HEPES, 100 U/ml penicillin, and 10 µg/ml streptomycin. Cells were cultured at 37°C in an incubator containing 5% CO2.

Detection of TM4SF5 mRNA expression in cell lines

To analyze the TM4SF5 expression, we performed RT-PCR. Total RNAs were extracted with an RNeasy Mini Kit (Qiagen), and the cDNA was synthesized as described previously [38]. The standard PCR reaction was performed for 25 cycles with the following primer sets: mouse GAPDH, 5'-ATGGTGAAGGTGCTGGTGCAACG-3' and 5'-GGTTGTCAATGGATCCTGTTGCCC-3' (501 bp); mouse TM4SF5, 5'-CGCTTACTTGCGAAATGACA-3' and 5'-TTTCTGCAATCGCCACACA-3' (174 bp), human β-actin, 5'-GGGTCAAGAGGATCTTATG-3' and 5'-CTTAAATCTCACGCACTATT-3' (500 bp); human TM4SF5, 5'-AGCTTGCAAGTCTGGCTCAT-3' and 5'-GCTGGATCCCACACAGTACT-3' (408 bp).

MTT assay

To evaluate the effect of the antibody on the growth of cells, an MTT assay was performed as described previously [48, 49]. Cells were treated with PBS, normal IgG, or anti-TM4SF5 monoclonal antibody (10 µg/ml) for up to 5 days. The MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide, Sigma-Aldrich) solution was added to each well and then the plates were incubated for 4 h at 37°C. The medium was removed, and the formazan crystals were solubilized in DMSO. The color development was measured using a spectrophotometer at 595 nm with a reference wavelength of 650 nm.

Confocal microscopy

Cells were cultured on glass cover slips in 4-well plates 18 h prior to treatment with the anti-hTM4SF5 monoclonal antibody or control IgG (10 µg/ml). After treatment with the antibody for the indicated time periods, the cells were fixed with 4% paraformaldehyde, permeabilized with PBS containing 0.1% Triton X-100, and stained with the anti-E-cadherin antibody (rabbit polyclonal Ab, Santa Cruz Biotechnology, sc-7870) or with anti-β-catenin antibody (rabbit polyclonal Ab, Upstate Biotechnology, #06-734), for 1 h. After extensive washing in PBS containing 0.1% Triton X-100, the samples were incubated with Alexa Flour 488 or Alexa Flour 594-conjugated goat anti-rabbit IgG (Invitrogen) for 1 h. The nuclei were stained with Hoechst 33258, and the
mounted samples were scanned with an LSM 710 (Carl Zeiss).

**Western blotting**

Proteins were separated by SDS-PAGE and transferred onto PVDF membranes (Pall Corporation). The membranes were incubated with primary antibody for 2 h, washed with PBST, and incubated in HRP-conjugated secondary antibody (Jackson ImmunoResearch Laboratories) for 1 h at room temperature. Blots were developed using ECL reagents (Intron Biotechnology).

**Biodistribution imaging in vivo**

5 mg/ml of the anti-TM4SF5 monoclonal antibody and IgG2a control (Bethyl Laboratories) in PBS solution was adjusted to contain 50 mM borate buffer (pH 8.5). The antibodies were conjugated with DyLight 755 and purified using a DyLight 755 Antibody Labeling Kit (Thermo Scientific). Fifty micrograms of DyLight 755-labeled anti-TM4SF5 antibody or DyLight 755-labeled IgG2a control were injected into the intraperitoneal cavity of BALB/c control mice or mice bearing CT-26 cell derived tumors. The distribution of the DyLight 755-labeled antibodies was quantified by in vivo fluorescence using a real-time IVIS imaging system 200 (Xenogen Corp.). To investigate the localization of the injected DyLight 755-labeled antibodies in colon tumor tissues, the tissues were removed at 72 h. The frozen tissues were cut into 4-µm-thick slices using a cryostat and stained with SYTOX Green dye for nuclei, and the mounted samples were examined with an LSM 710.

**Animals**

Mice were maintained under specific pathogen-free conditions in the Experimental Animal Center of Hallym University. Four-week-old male BALB/cAnCrj-nu/nu mice and BALB/c mice were purchased from OrientBio. Our animal studies were performed according to the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Veterinary Research & Quarantine Service of Korea. All procedures involving animal studies were approved by the Institutional Animal Care and Use Committee of Hallym University ( Permit Number: Hallym 2011-89, Hallym 2012-81-1). The mice were sacrificed under Zoletil 50+Rompun anesthesia with all efforts to minimize suffering.

**Colon cancer mouse model**

For the allograft assays, thirty BALB/c mice were inoculated subcutaneously in the dorsal right flank with $5 \times 10^6$ CT-26 cells in 50% Matrigel as previously described [40]. When tumors reached 5 mm in diameter, the mice were randomly divided into three treatment groups (8 mice/group): PBS, IgG control, and the anti-TM4SF5 monoclonal antibody. The antibodies (25 mg/kg) were injected twice weekly into the intraperitoneal cavity. Tumor diameters were measured using calipers at 2 day intervals for 18 days following the injection of CT-26 cells, and tumor volumes were calculated using the formula width$^2 \times$ length/2. Finally, the mice were sacrificed 18 days after CT-26 cells injection and the tumors were weighed. For the xenograft assays, thirty BALB/cAnCrj-nu/nu mice were inoculated subcutaneously in the dorsal right flank with $5 \times 10^6$ HT-29 cells containing 50% Matrigel. When tumors reached 5 mm in diameter, the mice were randomly divided into three treatment groups (8 mice/group): PBS, IgG control, and the anti-TM4SF5 monoclonal antibody. Six mice injected with neither cancer cells nor antibody were used as a control. The antibodies (25 mg/kg) were injected twice weekly into the intraperitoneal cavity. Tumor diameters were measured using calipers at 5 day intervals for 25 days following the injection of HT-29 cells, and tumor volumes were calculated using the formula width$^2 \times$ length/2. Finally, the mice were sacrificed 30 days after HT-29 cells injection and the tumors were weighed.

**Histology and immunohistochemistry**

The tumors were removed and fixed in a 4% buffered formalin solution overnight, embedded in paraffin using standard methods, and cut into 5-µm-thick sections. The sections were deparaffinized and then stained with hematoxylin and eosin (H&E). To evaluate the expression of TM4SF5, the deparaffinized sections were stained with the anti-TM4SF5 monoclonal antibody (10 µg/ml), according to standard procedures using a Histostain Plus kit. The samples were then counterstained with hematoxylin. All images were examined using a Nikon Eclipse E-200 microscope.

**Statistical analysis**

Results are expressed as mean ± standard deviation. Statistical significance between two samples was evaluated using the Student’s t test. A p-value of <0.05 was taken as statistically significant.

**ACKNOWLEDGEMENTS**

This research was supported by grants from the National Research Foundation (20121A2A2A01009887, 2013M3A9A9050126, 2013R1A2A2A03067981, 2012006695) funded by the Ministry of Science, ICT & Future Planning in the Republic of Korea.
The authors are grateful to Seung-Hae Kwon and Won Gyeong Ahn at the Chuncheon Center of the Korea Basic Science Institute for technical assistance in a real-time IVIS imaging system 200.

The authors declare no conflict of interests.

REFERENCES

1. World Health Organization. “Cause-specific mortality: regional estimates for 2000-2011”. http://www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html. Retrieved January, 2014.

2. Cappell MS. Pathophysiology, clinical presentation, and management of colon cancer. Gastroenterol Clin North Am. 2008; 37(1):1-24.

3. Wilkinson N and Scott-Conner CE. Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am. 2008; 37(1):253-267.

4. Goodwin RA and Asmis TR. Overview of systemic therapy for colorectal cancer. Clin Colon Rectal Surg. 2009; 22(4):251-256.

5. Robertson JM. The role of radiation therapy for colorectal cancer. Gastroenterol Clin North Am. 2008; 37(1):269-285.

6. Koido S, Ohkusa T, Homma S, Namiki Y, Takakura K, Saito K, Ito Z, Kobayashi H, Kajihara M, Uchiyama K, Arihiro S, Arakawa H, Okamoto M, Gong J and Nagayoshi K. Immunotherapy for colorectal cancer. World J Gastroenterol. 2013; 19(46):8531-8542.

7. Hanna MG, Jr. Immunotherapy with autologous tumor cell vaccines for treatment of occult disease in early stage colon cancer. Hum Vaccin Immunother. 2012; 8(8):1156-1160.

8. Janakiram NB, Mohammed A, Bronze MS and Rao CV. Prophylactic vaccine approach for colon and pancreatic cancers: present and future. Curr Med Chem. 2012; 19(22):3664-3678.

9. Boncheva V, Bonney SA, Brooks SE, Tangney M, O’Sullivan G, Mirnezami A and Guinn BA. New targets for the immunotherapy of colon cancer-does reactive disease hold the answer? Cancer Gene Ther. 2013; 20(3):157-168.

10. Buhrman JD and Slansky JE. Improving T cell responses to modified peptides in tumor vaccines. Immunol Res. 2013; 55(1-3):34-47.

11. Goffin JR and Zbuk K. Epidermal growth factor receptor: pathway, therapies, and pipeline. Clin Ther. 2013; 35(9):1282-1303.

12. Tomas A, Futter CE and Eden ER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol. 2014; 24(1):26-34.

13. Catalano V, Turdo A, Di Franco S, Dieli F, Todaro M and Stassi G. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol. 2013; 23(6 Pt B):522-532.

14. Sierra JR and Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011; 3(1 Suppl):S21-35.

15. Wong A and Ma BB. Personalizing therapy for colorectal cancer. Clin Gastroenterol Hepatol. 2014; 12(1):139-144.

16. Grady WM and Pritchard CC. Molecular alterations and biomarkers in colorectal cancer. Toxicol Pathol. 2014; 42(1):124-139.

17. Tanaka S and Arii S. Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies. J Gastroenterol. 2011; 46(3):289-296.

18. Siegel AB, Cohen EI, Oceana A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS, Jr., Rafii S and Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008; 26(18):2992-2998.

19. Markowska A, Lubin J, Madry R and Markowska J. Development of antiangiogenic therapies for ovarian cancer. Eur J Gynaecol Oncol. 2013; 34(4):303-306.

20. Harshman LC, Barbeau S, McMillian A and Srinivas S. A phase II study of bevacizumab and everolimus as treatment for refractory metastatic renal cell carcinoma. Clin Genitourin Cancer. 2013; 11(2):100-106.

21. Koukourakis GM, Sotiropoulou-Lontou A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol. 2011; 13(10):710-714.

22. Tol J and Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther. 2010; 32(3):437-453.

23. Keating GM. Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010; 70(8):1059-1078.

24. Levy S and Shoham T. The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol. 2005; 5(2):136-148.

25. Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005; 6(10):801-802.

26. Richardson MM, Jennings NK and Zhang XA. Tetraspanins and tumor progression. Clin Exp Metastasis. 2011; 28(3):261-270.

27. Anderson KR, Singer RA, Balderes DA, Hernandez-Lagunas H, Johnson CW, Artinger KB and Sussel L. The L6 domain tetraspanin Tm4sf4 regulates endocrine pancreas differentiation and directed cell migration. Development. 2011; 138(15):3213-3224.

28. Lekishvili T, Fromm E, Mujoomdar M and Berditchevski F. The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains. Nat Rev Mol Cell Biol. 2005; 6(10):801-811.

29. Richardson MM, Jennings NK and Zhang XA. Tetraspanins and tumor progression. Clin Exp Metastasis. 2011; 28(3):261-270.

30. Lekishvili T, Fromm E, Mujoomdar M and Berditchevski F. The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumour cell motility. J Cell Sci. 2008; 121(Pt 5):685-694.

31. Mazzucchelli A, Sciammetta SC, Carloni V, Cosmi L, Annunziato F, Harada T, Abruignani S and Pinzani M. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem. 2005; 280(12):11329-11339.

32. Anzai N, Lee Y, Youn BS, Fukuda S, Kim YJ, Mantel
C, Akashi M and Broxmeyer HE. C-kit associated with the transmembrane 4 superfamily proteins constitutes a functionally distinct subunit in human hematopoietic progenitors. Blood. 2002; 99(12):4413-4421.

31. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009; 9(1):40-55.

32. Haeuw JF, Goetsch L, Bailly C and Corvaia N. Tetraspanin CD151 as a target for antibody-based cancer immunotherapy. Biochem Soc Trans. 2011; 39(2):553-558.

33. Muller-Pillastl F, Wallrapp C, Lacher U, Friess H, Buchler M, Adler G and Gress TM. Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer. Gene. 1998; 208(1):25-30.

34. Lee SA, Lee SY, Cho IH, Oh MA, Kang ES, Kim YB, Seo WD, Choi S, Nam JO, Tamamori-Adachi M, Kitajima S, Ye SK, Kim S et al. Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial-mesenchymal transition in human hepatocarcinoma. J Clin Invest. 2008; 118(4):1354-1366.

35. Choi S, Lee SA, Kwak TK, Kim HJ, Lee MJ, Ye SK, Kim SH, Kim S and Lee JW. Cooperation between integrin alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity. Blood. 2009; 113(8):1845-1855.

36. Lee SA, Kim TY, Kwak TK, Kim H, Kim S, Lee HJ, Kim SH, Park KH, Kim HJ, Cho M and Lee JW. Transmembrane 4 L six family member 5 (TM4SF5) enhances migration and invasion of hepatocytes for effective metastasis. J Cell Biochem. 2010; 111(1):59-66.

37. Kim D, Kwon S, Rhee JW, Kim KD, Kim YE, Park CS, Choi MJ, Suh JG, Kim DS, Lee Y and Kwon HJ. Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol. 2011; 12:29.

38. Kwon S, Kim D, Park BK, Cho S, Kim KD, Kim YE, Park CS, Ahn HJ, Seo JN, Choi KC, Kim DS, Lee Y and Kwon HJ. Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers. PLoS One. 2012; 7(3):e33121.

39. Kwon S, Kim D, Park BK, Wu G, Park MC, Ha YW, Kwon HJ and Lee Y. Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model. Oncol Rep. 2013; 29(2):735-740.

40. Kwon S, Kim YE, Kim D, Park BK, Wu G, Kim TH, Choi SH, Kim DS, Kwon HJ and Lee Y. Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model. Biochem Biophys Res Commun. 2013; 435(1):134-139.

41. Kwon S, Kim YE, Park JA, Kim DS, Kwon HJ and Lee Y. Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model. BMB Rep. 2014; 47(4):215-220.

42. Kwon S, Choi KC, Kim YE, Ha YW, Kim D, Park BK, Guang Wu, Kim DS, Lee Y and Kwon HJ. Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma. Cancer Res. 2014; 74(14):3844-3856.

43. Brembeck FH1, Rosário M and Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr Opin Genet Dev. 2006; 16(1):51-59.

44. Ogino S, Shima K, Nosho K, Irahara N, Baba Y, Wolpin BM, Giovannucci EL, Meyerhardt JA and Fuchs CS. A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev. 2009; 18(6):1849-1858.

45. Wu YB, Huang YS, Xu YP, Sun YF, Yu DL, Zhang XQ, Long X, Zhu SQ, Zhou JL and Xu JJ. A high level of TM4SF5 is associated with human esophageal cancer progression and poor patient survival. Dig Dis Sci. 2013; 58:2623-2633.

46. Kovtun YV1, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA and Goldmacher VS. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res. 2006; 66(6):3214-3221.

47. Ducry L1 and Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem. 2010; 21(1):5-13.

48. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988; 48(3):589-601.

49. Kim HR, Heo YM, Jeong K, Kim YM, Jang HL, Lee KY, Yeo CY, Kim SH, Lee HK, Kim SR, Kim EG and Choi JK. FGF-2 inhibits TNF-α mediated apoptosis through upregulation of Bcl2-A1 and Bcl-xL in ATDC5 cells. BMB Rep. 2012; 45(5):287-292.